Skip to main content
Erschienen in: American Journal of Clinical Dermatology 4/2022

18.05.2022 | Review Article

The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy

verfasst von: Julie H. Wu, Sotonye Imadojemu, Avrom S. Caplan

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Sarcoidosis is a multisystem disorder of unknown etiology characterized by accumulation of granulomas in affected tissue. Cutaneous manifestations are among the most common extrapulmonary manifestations in sarcoidosis and can lead to disfiguring disease requiring chronic therapy. In many patients, skin disease may be the first recognized manifestation of sarcoidosis, necessitating a thorough evaluation for systemic involvement. Although the precise etiology of sarcoidosis and the pathogenic mechanisms leading to granuloma formation, persistence, or resolution remain unclear, recent research has led to significant advances in our understanding of this disease. This article reviews recent advances in epidemiology, sarcoidosis clinical assessment with a focus on the dermatologist’s role, disease pathogenesis, and new therapies in use and under investigation for cutaneous and systemic sarcoidosis.
Literatur
1.
Zurück zum Zitat Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Muller-Quernheim J. Sarcoidosis. Nat Rev Dis Primers. 2019;5(1):45.PubMedCrossRef Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Muller-Quernheim J. Sarcoidosis. Nat Rev Dis Primers. 2019;5(1):45.PubMedCrossRef
3.
Zurück zum Zitat Marcoval J, Mana J, Rubio M. Specific cutaneous lesions in patients with systemic sarcoidosis: relationship to severity and chronicity of disease. Clin Exp Dermatol. 2011;36(7):739–44.PubMedCrossRef Marcoval J, Mana J, Rubio M. Specific cutaneous lesions in patients with systemic sarcoidosis: relationship to severity and chronicity of disease. Clin Exp Dermatol. 2011;36(7):739–44.PubMedCrossRef
4.
Zurück zum Zitat Wanat KA, Rosenbach M. A practical approach to cutaneous sarcoidosis. Am J Clin Dermatol. 2014;15(4):283–97.PubMedCrossRef Wanat KA, Rosenbach M. A practical approach to cutaneous sarcoidosis. Am J Clin Dermatol. 2014;15(4):283–97.PubMedCrossRef
5.
Zurück zum Zitat Drent M, Crouser ED, Grunewald J. Challenges of sarcoidosis and its management. N Engl J Med. 2021;385(11):1018–32.PubMedCrossRef Drent M, Crouser ED, Grunewald J. Challenges of sarcoidosis and its management. N Engl J Med. 2021;385(11):1018–32.PubMedCrossRef
6.
Zurück zum Zitat Yamaguchi M, Hosoda Y, Sasaki R, Aoki K. Epidemiological study on sarcoidosis in Japan. Recent trends in incidence and prevalence rates and changes in epidemiological features. Sarcoidosis. 1989;6(2):138–46.PubMed Yamaguchi M, Hosoda Y, Sasaki R, Aoki K. Epidemiological study on sarcoidosis in Japan. Recent trends in incidence and prevalence rates and changes in epidemiological features. Sarcoidosis. 1989;6(2):138–46.PubMed
7.
Zurück zum Zitat Henke CE, Henke G, Elveback LR, Beard CM, Ballard DJ, Kurland LT. The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol. 1986;123(5):840–5.PubMedCrossRef Henke CE, Henke G, Elveback LR, Beard CM, Ballard DJ, Kurland LT. The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol. 1986;123(5):840–5.PubMedCrossRef
8.
Zurück zum Zitat Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):119–27.PubMed Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):119–27.PubMed
10.
Zurück zum Zitat Yanardag H, Pamuk ON, Karayel T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. Respir Med. 2003;97(8):978–82.PubMedCrossRef Yanardag H, Pamuk ON, Karayel T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. Respir Med. 2003;97(8):978–82.PubMedCrossRef
11.
Zurück zum Zitat Hattori T, Konno S, Shijubo N, Yamaguchi T, Sugiyama Y, Honma S, et al. Nationwide survey on the organ-specific prevalence and its interaction with sarcoidosis in Japan. Sci Rep. 2018;8(1):9440.PubMedPubMedCentralCrossRef Hattori T, Konno S, Shijubo N, Yamaguchi T, Sugiyama Y, Honma S, et al. Nationwide survey on the organ-specific prevalence and its interaction with sarcoidosis in Japan. Sci Rep. 2018;8(1):9440.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Dumas O, Abramovitz L, Wiley AS, Cozier YC, Camargo CA Jr. Epidemiology of sarcoidosis in a prospective cohort study of US women. Ann Am Thorac Soc. 2016;13(1):67–71.PubMedPubMedCentralCrossRef Dumas O, Abramovitz L, Wiley AS, Cozier YC, Camargo CA Jr. Epidemiology of sarcoidosis in a prospective cohort study of US women. Ann Am Thorac Soc. 2016;13(1):67–71.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Sawahata M, Sugiyama Y, Nakamura Y, Nakayama M, Mato N, Yamasawa H, et al. Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan. Respir Med. 2015;109(2):272–8.PubMedCrossRef Sawahata M, Sugiyama Y, Nakamura Y, Nakayama M, Mato N, Yamasawa H, et al. Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan. Respir Med. 2015;109(2):272–8.PubMedCrossRef
14.
Zurück zum Zitat Jamilloux Y, Bonnefoy M, Valeyre D, Varron L, Broussolle C, Seve P. Elderly-onset sarcoidosis: prevalence, clinical course, and treatment. Drugs Aging. 2013;30(12):969–78.PubMedCrossRef Jamilloux Y, Bonnefoy M, Valeyre D, Varron L, Broussolle C, Seve P. Elderly-onset sarcoidosis: prevalence, clinical course, and treatment. Drugs Aging. 2013;30(12):969–78.PubMedCrossRef
15.
Zurück zum Zitat Ungprasert P, Crowson CS, Matteson EL. Seasonal variation in incidence of sarcoidosis: a population-based study, 1976–2013. Thorax. 2016;71(12):1164–6.PubMedCrossRef Ungprasert P, Crowson CS, Matteson EL. Seasonal variation in incidence of sarcoidosis: a population-based study, 1976–2013. Thorax. 2016;71(12):1164–6.PubMedCrossRef
16.
Zurück zum Zitat Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J. 2016;48(6):1690–9.PubMedCrossRef Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J. 2016;48(6):1690–9.PubMedCrossRef
17.
Zurück zum Zitat Sikjaer MG, Hilberg O, Ibsen R, Lokke A. Sarcoidosis: a nationwide registry-based study of incidence, prevalence and diagnostic work-up. Respir Med. 2021;30(187): 106548.CrossRef Sikjaer MG, Hilberg O, Ibsen R, Lokke A. Sarcoidosis: a nationwide registry-based study of incidence, prevalence and diagnostic work-up. Respir Med. 2021;30(187): 106548.CrossRef
18.
Zurück zum Zitat Baughman RP, Field S, Costabel U, Crystal RG, Culver DA, Drent M, et al. Sarcoidosis in America. Analysis based on health care use. Ann Am Thorac Soc. 2016;13(8):1244–52.PubMedCrossRef Baughman RP, Field S, Costabel U, Crystal RG, Culver DA, Drent M, et al. Sarcoidosis in America. Analysis based on health care use. Ann Am Thorac Soc. 2016;13(8):1244–52.PubMedCrossRef
19.
Zurück zum Zitat Rybicki BA, Iannuzzi MC. Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med. 2007;28(1):22–35.PubMedCrossRef Rybicki BA, Iannuzzi MC. Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med. 2007;28(1):22–35.PubMedCrossRef
20.
Zurück zum Zitat Rybicki BA, Maliarik MJ, Major M, Popovich J Jr, Iannuzzi MC. Epidemiology, demographics, and genetics of sarcoidosis. Semin Respir Infect. 1998;13(3):166–73.PubMed Rybicki BA, Maliarik MJ, Major M, Popovich J Jr, Iannuzzi MC. Epidemiology, demographics, and genetics of sarcoidosis. Semin Respir Infect. 1998;13(3):166–73.PubMed
21.
Zurück zum Zitat Birnbaum AD, Rifkin LM. Sarcoidosis: sex-dependent variations in presentation and management. J Ophthalmol. 2014;2014: 236905.PubMedPubMedCentral Birnbaum AD, Rifkin LM. Sarcoidosis: sex-dependent variations in presentation and management. J Ophthalmol. 2014;2014: 236905.PubMedPubMedCentral
22.
Zurück zum Zitat Byg KE, Milman N, Hansen S. Sarcoidosis in Denmark 1980–1994. A registry-based incidence study comprising 5536 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(1):46–52.PubMed Byg KE, Milman N, Hansen S. Sarcoidosis in Denmark 1980–1994. A registry-based incidence study comprising 5536 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(1):46–52.PubMed
23.
Zurück zum Zitat Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950–1982. Epidemiology and clinical picture. Sarcoidosis. 1990;7(1):50–7.PubMed Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950–1982. Epidemiology and clinical picture. Sarcoidosis. 1990;7(1):50–7.PubMed
24.
Zurück zum Zitat Morimoto T, Azuma A, Abe S, Usuki J, Kudoh S, Sugisaki K, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008;31(2):372–9.PubMedCrossRef Morimoto T, Azuma A, Abe S, Usuki J, Kudoh S, Sugisaki K, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008;31(2):372–9.PubMedCrossRef
25.
Zurück zum Zitat Yoon HY, Kim HM, Kim YJ, Song JW. Prevalence and incidence of sarcoidosis in Korea: a nationwide population-based study. Respir Res. 2018;19(1):158.PubMedPubMedCentralCrossRef Yoon HY, Kim HM, Kim YJ, Song JW. Prevalence and incidence of sarcoidosis in Korea: a nationwide population-based study. Respir Res. 2018;19(1):158.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Cozier YC, Berman JS, Palmer JR, Boggs DA, Serlin DM, Rosenberg L. Sarcoidosis in black women in the United States: data from the Black Women’s Health Study. Chest. 2011;139(1):144–50.PubMedCrossRef Cozier YC, Berman JS, Palmer JR, Boggs DA, Serlin DM, Rosenberg L. Sarcoidosis in black women in the United States: data from the Black Women’s Health Study. Chest. 2011;139(1):144–50.PubMedCrossRef
27.
Zurück zum Zitat Tukey MH, Berman JS, Boggs DA, White LF, Rosenberg L, Cozier YC. Mortality among African American women with sarcoidosis: data from the Black Women’s Health Study. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(2):128–33.PubMed Tukey MH, Berman JS, Boggs DA, White LF, Rosenberg L, Cozier YC. Mortality among African American women with sarcoidosis: data from the Black Women’s Health Study. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(2):128–33.PubMed
28.
Zurück zum Zitat Kassamali B, Villa-Ruiz C, Kus KJB, Mazori DR, Kassamali AA, Gizelis O, Vleugels RA, LaChance AH, Imadojemu S. Increased risk of systemic and cardiac sarcoidosis in Black patients with cutaneous sarcoidosis. J Am Acad Dermatol. 2022;86(5):1178–80.PubMedCrossRef Kassamali B, Villa-Ruiz C, Kus KJB, Mazori DR, Kassamali AA, Gizelis O, Vleugels RA, LaChance AH, Imadojemu S. Increased risk of systemic and cardiac sarcoidosis in Black patients with cutaneous sarcoidosis. J Am Acad Dermatol. 2022;86(5):1178–80.PubMedCrossRef
29.
Zurück zum Zitat Evans M, Sharma O, LaBree L, Smith RE, Rao NA. Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis. Ophthalmology. 2007;114(2):325–33.PubMedCrossRef Evans M, Sharma O, LaBree L, Smith RE, Rao NA. Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis. Ophthalmology. 2007;114(2):325–33.PubMedCrossRef
30.
Zurück zum Zitat Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest. 2015;147(2):438–49.PubMedCrossRef Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest. 2015;147(2):438–49.PubMedCrossRef
31.
Zurück zum Zitat Iwai K, Sekiguti M, Hosoda Y, DeRemee RA, Tazelaar HD, Sharma OP, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11(1):26–31.PubMed Iwai K, Sekiguti M, Hosoda Y, DeRemee RA, Tazelaar HD, Sharma OP, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11(1):26–31.PubMed
32.
Zurück zum Zitat Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979–1991: an analysis of multiple-cause mortality data. Am J Med. 1996;100(4):423–7.PubMedCrossRef Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979–1991: an analysis of multiple-cause mortality data. Am J Med. 1996;100(4):423–7.PubMedCrossRef
33.
Zurück zum Zitat Varron L, Cottin V, Schott AM, Broussolle C, Seve P. Late-onset sarcoidosis: a comparative study. Medicine (Baltimore). 2012;91(3):137–43.CrossRef Varron L, Cottin V, Schott AM, Broussolle C, Seve P. Late-onset sarcoidosis: a comparative study. Medicine (Baltimore). 2012;91(3):137–43.CrossRef
34.
Zurück zum Zitat Ungprasert P, Wetter DA, Crowson CS, Matteson EL. Epidemiology of cutaneous sarcoidosis, 1976–2013: a population-based study from Olmsted County, Minnesota. J Eur Acad Dermatol Venereol. 2016;30(10):1799–804.PubMedPubMedCentralCrossRef Ungprasert P, Wetter DA, Crowson CS, Matteson EL. Epidemiology of cutaneous sarcoidosis, 1976–2013: a population-based study from Olmsted County, Minnesota. J Eur Acad Dermatol Venereol. 2016;30(10):1799–804.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Sverrild A, Backer V, Kyvik KO, Kaprio J, Milman N, Svendsen CB, et al. Heredity in sarcoidosis: a registry-based twin study. Thorax. 2008;63(10):894–6.PubMedCrossRef Sverrild A, Backer V, Kyvik KO, Kaprio J, Milman N, Svendsen CB, et al. Heredity in sarcoidosis: a registry-based twin study. Thorax. 2008;63(10):894–6.PubMedCrossRef
36.
Zurück zum Zitat Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, et al. Familial aggregation of sarcoidosis. A case–control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164(11):2085–91.PubMedCrossRef Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, et al. Familial aggregation of sarcoidosis. A case–control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164(11):2085–91.PubMedCrossRef
37.
Zurück zum Zitat Rybicki BA, Kirkey KL, Major M, Maliarik MJ, Popovich J Jr, Chase GA, et al. Familial risk ratio of sarcoidosis in African–American sibs and parents. Am J Epidemiol. 2001;153(2):188–93.PubMedCrossRef Rybicki BA, Kirkey KL, Major M, Maliarik MJ, Popovich J Jr, Chase GA, et al. Familial risk ratio of sarcoidosis in African–American sibs and parents. Am J Epidemiol. 2001;153(2):188–93.PubMedCrossRef
38.
Zurück zum Zitat Rossides M, Grunewald J, Eklund A, Kullberg S, Di Giuseppe D, Askling J, Arkema EV. Familial aggregation and heritability of sarcoidosis: a Swedish nested case-control study. Eur Respir J. 2018;52(2):1800385.PubMedCrossRef Rossides M, Grunewald J, Eklund A, Kullberg S, Di Giuseppe D, Askling J, Arkema EV. Familial aggregation and heritability of sarcoidosis: a Swedish nested case-control study. Eur Respir J. 2018;52(2):1800385.PubMedCrossRef
39.
Zurück zum Zitat Cleven KL, Ye K, Zeig-Owens R, Hena KM, Montagna C, Shan J, et al. Genetic variants associated with FDNY WTC-related sarcoidosis. Int J Environ Res Public Health. 2019;16(10):1830.PubMedCentralCrossRef Cleven KL, Ye K, Zeig-Owens R, Hena KM, Montagna C, Shan J, et al. Genetic variants associated with FDNY WTC-related sarcoidosis. Int J Environ Res Public Health. 2019;16(10):1830.PubMedCentralCrossRef
40.
Zurück zum Zitat Levin AM, Adrianto I, Datta I, Iannuzzi MC, Trudeau S, Li J, et al. Association of HLA-DRB1 with sarcoidosis susceptibility and progression in African Americans. Am J Respir Cell Mol Biol. 2015;53(2):206–16.PubMedPubMedCentralCrossRef Levin AM, Adrianto I, Datta I, Iannuzzi MC, Trudeau S, Li J, et al. Association of HLA-DRB1 with sarcoidosis susceptibility and progression in African Americans. Am J Respir Cell Mol Biol. 2015;53(2):206–16.PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Rivera NV, Patasova K, Kullberg S, Diaz-Gallo LM, Iseda T, Bengtsson C, et al. A gene–environment interaction between smoking and gene polymorphisms provides a high risk of two subgroups of sarcoidosis. Sci Rep. 2019;9(1):18633.PubMedPubMedCentralCrossRef Rivera NV, Patasova K, Kullberg S, Diaz-Gallo LM, Iseda T, Bengtsson C, et al. A gene–environment interaction between smoking and gene polymorphisms provides a high risk of two subgroups of sarcoidosis. Sci Rep. 2019;9(1):18633.PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Zhou H, Diao M, Zhang M. The association between ANXA11 gene polymorphisms and sarcoidosis: a meta-analysis and systematic review. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(2):102–11.PubMed Zhou H, Diao M, Zhang M. The association between ANXA11 gene polymorphisms and sarcoidosis: a meta-analysis and systematic review. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(2):102–11.PubMed
43.
Zurück zum Zitat Wolin A, Lahtela EL, Anttila V, Petrek M, Grunewald J, van Moorsel CHM, et al. SNP variants in major histocompatibility complex are associated with sarcoidosis susceptibility—a joint analysis in four European populations. Front Immunol. 2017;8:422.PubMedPubMedCentralCrossRef Wolin A, Lahtela EL, Anttila V, Petrek M, Grunewald J, van Moorsel CHM, et al. SNP variants in major histocompatibility complex are associated with sarcoidosis susceptibility—a joint analysis in four European populations. Front Immunol. 2017;8:422.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Bello GA, Adrianto I, Dumancas GG, Levin AM, Iannuzzi MC, Rybicki BA, et al. Role of NOD2 pathway genes in sarcoidosis cases with clinical characteristics of Blau syndrome. Am J Respir Crit Care Med. 2015;192(9):1133–5.PubMedPubMedCentralCrossRef Bello GA, Adrianto I, Dumancas GG, Levin AM, Iannuzzi MC, Rybicki BA, et al. Role of NOD2 pathway genes in sarcoidosis cases with clinical characteristics of Blau syndrome. Am J Respir Crit Care Med. 2015;192(9):1133–5.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Schnerch J, Prasse A, Vlachakis D, Schuchardt KL, Pechkovsky DV, Goldmann T, et al. Functional toll-like receptor 9 expression and CXCR3 ligand release in pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 2016;55(5):749–57.PubMedCrossRef Schnerch J, Prasse A, Vlachakis D, Schuchardt KL, Pechkovsky DV, Goldmann T, et al. Functional toll-like receptor 9 expression and CXCR3 ligand release in pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 2016;55(5):749–57.PubMedCrossRef
46.
Zurück zum Zitat Calender A, Weichhart T, Valeyre D, Pacheco Y. Current insights in genetics of sarcoidosis: functional and clinical impacts. J Clin Med. 2020;9(8):2633.PubMedCentralCrossRef Calender A, Weichhart T, Valeyre D, Pacheco Y. Current insights in genetics of sarcoidosis: functional and clinical impacts. J Clin Med. 2020;9(8):2633.PubMedCentralCrossRef
47.
Zurück zum Zitat Fritz D, Ferwerda B, Brouwer MC, van de Beek D. Whole genome sequencing identifies variants associated with sarcoidosis in a family with a high prevalence of sarcoidosis. Clin Rheumatol. 2021;40(9):3735–43.PubMedPubMedCentralCrossRef Fritz D, Ferwerda B, Brouwer MC, van de Beek D. Whole genome sequencing identifies variants associated with sarcoidosis in a family with a high prevalence of sarcoidosis. Clin Rheumatol. 2021;40(9):3735–43.PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Lahtela E, Kankainen M, Sinisalo J, Selroos O, Lokki ML. Exome sequencing identifies susceptibility loci for sarcoidosis prognosis. Front Immunol. 2019;10:2964.PubMedPubMedCentralCrossRef Lahtela E, Kankainen M, Sinisalo J, Selroos O, Lokki ML. Exome sequencing identifies susceptibility loci for sarcoidosis prognosis. Front Immunol. 2019;10:2964.PubMedPubMedCentralCrossRef
49.
Zurück zum Zitat Kishore A, Petersen BS, Nutsua M, Muller-Quernheim J, Franke A, Fischer A, et al. Whole-exome sequencing identifies rare genetic variations in German families with pulmonary sarcoidosis. Hum Genet. 2018;137(9):705–16.PubMedCrossRef Kishore A, Petersen BS, Nutsua M, Muller-Quernheim J, Franke A, Fischer A, et al. Whole-exome sequencing identifies rare genetic variations in German families with pulmonary sarcoidosis. Hum Genet. 2018;137(9):705–16.PubMedCrossRef
50.
Zurück zum Zitat Calender A, Lim CX, Weichhart T, Buisson A, Besnard V, Rollat-Farnier PA, Bardel C, Roy P, Cottin V, Devouassoux G, Finat A, Pinson S, Lebecque S, Nunes H, Israel-Biet D, Bentaher A, Valeyre D, Pacheco Y; in the frame of GSF (Group Sarcoidosis France). Exome sequencing and pathogenicity-network analysis of five French families implicate mTOR signalling and autophagy in familial sarcoidosis. Eur Respir J. 2019;54(2):1900430.PubMedCrossRef Calender A, Lim CX, Weichhart T, Buisson A, Besnard V, Rollat-Farnier PA, Bardel C, Roy P, Cottin V, Devouassoux G, Finat A, Pinson S, Lebecque S, Nunes H, Israel-Biet D, Bentaher A, Valeyre D, Pacheco Y; in the frame of GSF (Group Sarcoidosis France). Exome sequencing and pathogenicity-network analysis of five French families implicate mTOR signalling and autophagy in familial sarcoidosis. Eur Respir J. 2019;54(2):1900430.PubMedCrossRef
51.
Zurück zum Zitat Suwinski P, Ong C, Ling MHT, Poh YM, Khan AM, Ong HS. Advancing personalized medicine through the application of whole exome sequencing and big data analytics. Front Genet. 2019;10:49.PubMedPubMedCentralCrossRef Suwinski P, Ong C, Ling MHT, Poh YM, Khan AM, Ong HS. Advancing personalized medicine through the application of whole exome sequencing and big data analytics. Front Genet. 2019;10:49.PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–84.PubMedCrossRef Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–84.PubMedCrossRef
53.
Zurück zum Zitat Floss DM, Moll JM, Scheller J. IL-12 and IL-23-close relatives with structural homologies but distinct immunological functions. Cells. 2020;9(10):2184.PubMedCentralCrossRef Floss DM, Moll JM, Scheller J. IL-12 and IL-23-close relatives with structural homologies but distinct immunological functions. Cells. 2020;9(10):2184.PubMedCentralCrossRef
54.
55.
Zurück zum Zitat Sakthivel P, Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol. 2017;24(1):59–65.PubMedCrossRef Sakthivel P, Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol. 2017;24(1):59–65.PubMedCrossRef
56.
Zurück zum Zitat Wang A, Singh K, Ibrahim W, King B, Damsky W. The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: a review of the literature. Yale J Biol Med. 2020;93(1):187–95.PubMedPubMedCentral Wang A, Singh K, Ibrahim W, King B, Damsky W. The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: a review of the literature. Yale J Biol Med. 2020;93(1):187–95.PubMedPubMedCentral
57.
Zurück zum Zitat Zhou T, Casanova N, Pouladi N, Wang T, Lussier Y, Knox KS, et al. Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature. Sci Rep. 2017;7(1):4237.PubMedPubMedCentralCrossRef Zhou T, Casanova N, Pouladi N, Wang T, Lussier Y, Knox KS, et al. Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature. Sci Rep. 2017;7(1):4237.PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Damsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of multiorgan sarcoidosis with tofacitinib. ACR Open Rheumatol. 2020;2(2):106–9.PubMedPubMedCentralCrossRef Damsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of multiorgan sarcoidosis with tofacitinib. ACR Open Rheumatol. 2020;2(2):106–9.PubMedPubMedCentralCrossRef
59.
Zurück zum Zitat Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82(3):612–21.PubMedCrossRef Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82(3):612–21.PubMedCrossRef
60.
Zurück zum Zitat Moller DR, Rybicki BA, Hamzeh NY, Montgomery CG, Chen ES, Drake W, et al. Genetic, immunologic, and environmental basis of sarcoidosis. Ann Am Thorac Soc. 2017;14(Supplement_6):S429–36.PubMedPubMedCentralCrossRef Moller DR, Rybicki BA, Hamzeh NY, Montgomery CG, Chen ES, Drake W, et al. Genetic, immunologic, and environmental basis of sarcoidosis. Ann Am Thorac Soc. 2017;14(Supplement_6):S429–36.PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Esteves T, Aparicio G, Garcia-Patos V. Is there any association between sarcoidosis and infectious agents?: A systematic review and meta-analysis. BMC Pulm Med. 2016;16(1):165.PubMedPubMedCentralCrossRef Esteves T, Aparicio G, Garcia-Patos V. Is there any association between sarcoidosis and infectious agents?: A systematic review and meta-analysis. BMC Pulm Med. 2016;16(1):165.PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Zhou Y, Hu Y, Li H. Role of propionibacterium acnes in sarcoidosis: a meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(4):262–7.PubMed Zhou Y, Hu Y, Li H. Role of propionibacterium acnes in sarcoidosis: a meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(4):262–7.PubMed
63.
Zurück zum Zitat Knoell KA, Hendrix JD Jr, Stoler MH, Patterson JW, Montes CM. Absence of human herpesvirus 8 in sarcoidosis and crohn disease granulomas. Arch Dermatol. 2005;141(7):909–10.PubMedCrossRef Knoell KA, Hendrix JD Jr, Stoler MH, Patterson JW, Montes CM. Absence of human herpesvirus 8 in sarcoidosis and crohn disease granulomas. Arch Dermatol. 2005;141(7):909–10.PubMedCrossRef
64.
Zurück zum Zitat Derler AM, Eisendle K, Baltaci M, Obermoser G, Zelger B. High prevalence of “Borrelia-like” organisms in skin biopsies of sarcoidosis patients from Western Austria. J Cutan Pathol. 2009;36(12):1262–8.PubMedCrossRef Derler AM, Eisendle K, Baltaci M, Obermoser G, Zelger B. High prevalence of “Borrelia-like” organisms in skin biopsies of sarcoidosis patients from Western Austria. J Cutan Pathol. 2009;36(12):1262–8.PubMedCrossRef
65.
Zurück zum Zitat Shields BE, Perelygina L, Samimi S, Haun P, Leung T, Abernathy E, et al. Granulomatous dermatitis associated with rubella virus infection in an adult with immunodeficiency. JAMA Dermatol. 2021;157(7):842–7.PubMedCrossRef Shields BE, Perelygina L, Samimi S, Haun P, Leung T, Abernathy E, et al. Granulomatous dermatitis associated with rubella virus infection in an adult with immunodeficiency. JAMA Dermatol. 2021;157(7):842–7.PubMedCrossRef
66.
Zurück zum Zitat Chen ES, Moller DR. Sarcoidosis—scientific progress and clinical challenges. Nat Rev Rheumatol. 2011;7(8):457–67.PubMedCrossRef Chen ES, Moller DR. Sarcoidosis—scientific progress and clinical challenges. Nat Rev Rheumatol. 2011;7(8):457–67.PubMedCrossRef
67.
Zurück zum Zitat Drake WP, Culver DA, Baughman RP, Judson MA, Crouser ED, James WE, et al. Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis. Chest. 2021;159(5):1902–12.PubMedCrossRef Drake WP, Culver DA, Baughman RP, Judson MA, Crouser ED, James WE, et al. Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis. Chest. 2021;159(5):1902–12.PubMedCrossRef
68.
Zurück zum Zitat Chen ES, Wahlstrom J, Song Z, Willett MH, Wiken M, Yung RC, et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol. 2008;181(12):8784–96.PubMedCrossRef Chen ES, Wahlstrom J, Song Z, Willett MH, Wiken M, Yung RC, et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol. 2008;181(12):8784–96.PubMedCrossRef
69.
Zurück zum Zitat Song Z, Marzilli L, Greenlee BM, Chen ES, Silver RF, Askin FB, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. 2005;201(5):755–67.PubMedPubMedCentralCrossRef Song Z, Marzilli L, Greenlee BM, Chen ES, Silver RF, Askin FB, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. 2005;201(5):755–67.PubMedPubMedCentralCrossRef
70.
Zurück zum Zitat Bindoli S, Dagan A, Torres-Ruiz JJ, Perricone C, Bizjak M, Doria A, et al. Sarcoidosis and autoimmunity: from genetic background to environmental factors. Isr Med Assoc J. 2016;18(3–4):197–202.PubMed Bindoli S, Dagan A, Torres-Ruiz JJ, Perricone C, Bizjak M, Doria A, et al. Sarcoidosis and autoimmunity: from genetic background to environmental factors. Isr Med Assoc J. 2016;18(3–4):197–202.PubMed
72.
Zurück zum Zitat Armbruster C, Dekan G, Hovorka A. Granulomatous pneumonitis and mediastinal lymphadenopathy due to photocopier toner dust. Lancet. 1996;348(9028):690.PubMedCrossRef Armbruster C, Dekan G, Hovorka A. Granulomatous pneumonitis and mediastinal lymphadenopathy due to photocopier toner dust. Lancet. 1996;348(9028):690.PubMedCrossRef
74.
Zurück zum Zitat Kim YC, Triffet MK, Gibson LE. Foreign bodies in sarcoidosis. Am J Dermatopathol. 2000;22(5):408–12.PubMedCrossRef Kim YC, Triffet MK, Gibson LE. Foreign bodies in sarcoidosis. Am J Dermatopathol. 2000;22(5):408–12.PubMedCrossRef
75.
Zurück zum Zitat Ball NJ, Kho GT, Martinka M. The histologic spectrum of cutaneous sarcoidosis: a study of twenty-eight cases. J Cutan Pathol. 2004;31(2):160–8.PubMedCrossRef Ball NJ, Kho GT, Martinka M. The histologic spectrum of cutaneous sarcoidosis: a study of twenty-eight cases. J Cutan Pathol. 2004;31(2):160–8.PubMedCrossRef
76.
Zurück zum Zitat Mayer AS, Hamzeh N, Maier LA. Sarcoidosis and chronic beryllium disease: similarities and differences. Semin Respir Crit Care Med. 2014;35(3):316–29.PubMedCrossRef Mayer AS, Hamzeh N, Maier LA. Sarcoidosis and chronic beryllium disease: similarities and differences. Semin Respir Crit Care Med. 2014;35(3):316–29.PubMedCrossRef
77.
Zurück zum Zitat Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324–30.PubMedCrossRef Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324–30.PubMedCrossRef
78.
Zurück zum Zitat Izbicki G, Chavko R, Banauch GI, Weiden MD, Berger KI, Aldrich TK, et al. World Trade Center “sarcoid-like” granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest. 2007;131(5):1414–23.PubMedCrossRef Izbicki G, Chavko R, Banauch GI, Weiden MD, Berger KI, Aldrich TK, et al. World Trade Center “sarcoid-like” granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest. 2007;131(5):1414–23.PubMedCrossRef
79.
Zurück zum Zitat Hena KM, Yip J, Jaber N, Goldfarb D, Fullam K, Cleven K, et al. Clinical course of sarcoidosis in world trade center-exposed firefighters. Chest. 2018;153(1):114–23.PubMedCrossRef Hena KM, Yip J, Jaber N, Goldfarb D, Fullam K, Cleven K, et al. Clinical course of sarcoidosis in world trade center-exposed firefighters. Chest. 2018;153(1):114–23.PubMedCrossRef
80.
Zurück zum Zitat Papanikolaou IC, Tabila B, Tabila K, Borok Z, Sharma O, Gould MK. Vitamin D status in sarcoidosis: a cross-sectional study. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(2):154–9.PubMedPubMedCentral Papanikolaou IC, Tabila B, Tabila K, Borok Z, Sharma O, Gould MK. Vitamin D status in sarcoidosis: a cross-sectional study. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(2):154–9.PubMedPubMedCentral
81.
Zurück zum Zitat Kiani A, Abedini A, Adcock IM, Mirenayat MS, Taghavi K, Mortaz E, et al. Association between vitamin D deficiencies in sarcoidosis with disease activity, course of disease and stages of lung involvements. J Med Biochem. 2018;37(2):103–9.PubMedPubMedCentralCrossRef Kiani A, Abedini A, Adcock IM, Mirenayat MS, Taghavi K, Mortaz E, et al. Association between vitamin D deficiencies in sarcoidosis with disease activity, course of disease and stages of lung involvements. J Med Biochem. 2018;37(2):103–9.PubMedPubMedCentralCrossRef
83.
Zurück zum Zitat Hamada K, Nagai S, Tsutsumi T, Izumi T. Ionized calcium and 1,25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis. Eur Respir J. 1998;11(5):1015–20.PubMedCrossRef Hamada K, Nagai S, Tsutsumi T, Izumi T. Ionized calcium and 1,25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis. Eur Respir J. 1998;11(5):1015–20.PubMedCrossRef
84.
Zurück zum Zitat Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med. 1989;111(5):437–8.PubMedCrossRef Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med. 1989;111(5):437–8.PubMedCrossRef
85.
Zurück zum Zitat Wu CH, Chung PI, Wu CY, Chen YT, Chiu YW, Chang YT, et al. Comorbid autoimmune diseases in patients with sarcoidosis: a nationwide case-control study in Taiwan. J Dermatol. 2017;44(4):423–30.PubMedCrossRef Wu CH, Chung PI, Wu CY, Chen YT, Chiu YW, Chang YT, et al. Comorbid autoimmune diseases in patients with sarcoidosis: a nationwide case-control study in Taiwan. J Dermatol. 2017;44(4):423–30.PubMedCrossRef
86.
Zurück zum Zitat Migita K, Udono M, Kinoshita A, Osumi M, Ito M, Miyashita T, et al. Lupus erythematosus and sarcoidosis. Clin Rheumatol. 2005;24(3):312–3.PubMedCrossRef Migita K, Udono M, Kinoshita A, Osumi M, Ito M, Miyashita T, et al. Lupus erythematosus and sarcoidosis. Clin Rheumatol. 2005;24(3):312–3.PubMedCrossRef
87.
Zurück zum Zitat Santiago T, Santiago M, Rovisco J, Ferreira J, Duarte C, Malcata A, et al. Coexisting primary Sjogren’s syndrome and sarcoidosis: coincidence, mutually exclusive conditions or syndrome? Rheumatol Int. 2014;34(11):1619–22.PubMedCrossRef Santiago T, Santiago M, Rovisco J, Ferreira J, Duarte C, Malcata A, et al. Coexisting primary Sjogren’s syndrome and sarcoidosis: coincidence, mutually exclusive conditions or syndrome? Rheumatol Int. 2014;34(11):1619–22.PubMedCrossRef
88.
Zurück zum Zitat Antonelli A, Fazzi P, Fallahi P, Ferrari SM, Ferrannini E. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest. 2006;130(2):526–32.PubMedCrossRef Antonelli A, Fazzi P, Fallahi P, Ferrari SM, Ferrannini E. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest. 2006;130(2):526–32.PubMedCrossRef
89.
Zurück zum Zitat Starshinova AA, Malkova AM, Basantsova NY, Zinchenko YS, Kudryavtsev IV, Ershov GA, et al. Sarcoidosis as an autoimmune disease. Front Immunol. 2019;10:2933.PubMedCrossRef Starshinova AA, Malkova AM, Basantsova NY, Zinchenko YS, Kudryavtsev IV, Ershov GA, et al. Sarcoidosis as an autoimmune disease. Front Immunol. 2019;10:2933.PubMedCrossRef
90.
Zurück zum Zitat Musaelyan A, Lapin S, Nazarov V, Tkachenko O, Gilburd B, Mazing A, et al. Vimentin as antigenic target in autoimmunity: a comprehensive review. Autoimmun Rev. 2018;17(9):926–34.PubMedCrossRef Musaelyan A, Lapin S, Nazarov V, Tkachenko O, Gilburd B, Mazing A, et al. Vimentin as antigenic target in autoimmunity: a comprehensive review. Autoimmun Rev. 2018;17(9):926–34.PubMedCrossRef
91.
Zurück zum Zitat Kinloch AJ, Kaiser Y, Wolfgeher D, Ai J, Eklund A, Clark MR, et al. In situ humoral immunity to vimentin in HLA-DRB1*03(+) patients with pulmonary sarcoidosis. Front Immunol. 2018;9:1516.PubMedPubMedCentralCrossRef Kinloch AJ, Kaiser Y, Wolfgeher D, Ai J, Eklund A, Clark MR, et al. In situ humoral immunity to vimentin in HLA-DRB1*03(+) patients with pulmonary sarcoidosis. Front Immunol. 2018;9:1516.PubMedPubMedCentralCrossRef
92.
Zurück zum Zitat Song M, Manansala M, Parmar PJ, Ascoli C, Rubinstein I, Sweiss NJ. Sarcoidosis and autoimmunity. Curr Opin Pulm Med. 2021;27(5):448–54.PubMedCrossRef Song M, Manansala M, Parmar PJ, Ascoli C, Rubinstein I, Sweiss NJ. Sarcoidosis and autoimmunity. Curr Opin Pulm Med. 2021;27(5):448–54.PubMedCrossRef
93.
Zurück zum Zitat Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol. 2012;66(5):699 e1-18 (quiz 717–8).CrossRef Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol. 2012;66(5):699 e1-18 (quiz 717–8).CrossRef
94.
Zurück zum Zitat Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. Lancet Respir Med. 2018;6(5):389–402.PubMedCrossRef Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. Lancet Respir Med. 2018;6(5):389–402.PubMedCrossRef
95.
Zurück zum Zitat Steffen M, Petersen J, Oldigs M, Karmeier A, Magnussen H, Thiele HG, et al. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J Allergy Clin Immunol. 1993;91(4):939–49.PubMedCrossRef Steffen M, Petersen J, Oldigs M, Karmeier A, Magnussen H, Thiele HG, et al. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J Allergy Clin Immunol. 1993;91(4):939–49.PubMedCrossRef
96.
Zurück zum Zitat Celada LJ, Drake WP. Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy? Immunotherapy. 2015;7(1):57–66.PubMedCrossRef Celada LJ, Drake WP. Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy? Immunotherapy. 2015;7(1):57–66.PubMedCrossRef
97.
Zurück zum Zitat Ostadkarampour M, Eklund A, Moller D, Glader P, Olgart Hoglund C, Linden A, et al. Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Lofgren’s syndrome. Clin Exp Immunol. 2014;178(2):342–52.PubMedPubMedCentralCrossRef Ostadkarampour M, Eklund A, Moller D, Glader P, Olgart Hoglund C, Linden A, et al. Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Lofgren’s syndrome. Clin Exp Immunol. 2014;178(2):342–52.PubMedPubMedCentralCrossRef
98.
Zurück zum Zitat Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp (Warsz). 2015;63(6):435–49.CrossRef Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp (Warsz). 2015;63(6):435–49.CrossRef
99.
100.
Zurück zum Zitat Ten Berge B, Paats MS, Bergen IM, van den Blink B, Hoogsteden HC, Lambrecht BN, et al. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford). 2012;51(1):37–46.CrossRef Ten Berge B, Paats MS, Bergen IM, van den Blink B, Hoogsteden HC, Lambrecht BN, et al. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford). 2012;51(1):37–46.CrossRef
101.
Zurück zum Zitat Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax. 2011;66(2):144–50.PubMedCrossRef Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax. 2011;66(2):144–50.PubMedCrossRef
102.
Zurück zum Zitat Wu W, Jin M, Wang Y, Liu B, Shen D, Chen P, et al. Overexpression of IL-17RC associated with ocular sarcoidosis. J Transl Med. 2014;31(12):152.CrossRef Wu W, Jin M, Wang Y, Liu B, Shen D, Chen P, et al. Overexpression of IL-17RC associated with ocular sarcoidosis. J Transl Med. 2014;31(12):152.CrossRef
103.
Zurück zum Zitat Song J, Zhao M, Li Q, Lu L, Zhou Y, Zhang Y, et al. IL-17A Can Promote propionibacterium acnes-induced sarcoidosis-like granulomatosis in mice. Front Immunol. 2019;10:1923.PubMedPubMedCentralCrossRef Song J, Zhao M, Li Q, Lu L, Zhou Y, Zhang Y, et al. IL-17A Can Promote propionibacterium acnes-induced sarcoidosis-like granulomatosis in mice. Front Immunol. 2019;10:1923.PubMedPubMedCentralCrossRef
104.
Zurück zum Zitat Ramstein J, Broos CE, Simpson LJ, Ansel KM, Sun SA, Ho ME, et al. IFN-gamma-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am J Respir Crit Care Med. 2016;193(11):1281–91.PubMedPubMedCentralCrossRef Ramstein J, Broos CE, Simpson LJ, Ansel KM, Sun SA, Ho ME, et al. IFN-gamma-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am J Respir Crit Care Med. 2016;193(11):1281–91.PubMedPubMedCentralCrossRef
105.
Zurück zum Zitat Zhou ER, Arce S. Key players and biomarkers of the adaptive immune system in the pathogenesis of sarcoidosis. Int J Mol Sci. 2020;21(19):7398.PubMedCentralCrossRef Zhou ER, Arce S. Key players and biomarkers of the adaptive immune system in the pathogenesis of sarcoidosis. Int J Mol Sci. 2020;21(19):7398.PubMedCentralCrossRef
106.
Zurück zum Zitat Bauer L, Müller LJ, Volkers SM, Heinrich F, Mashreghi MF, Ruppert C, Sander LE, Hutloff A. Follicular Helper-like T Cells in the Lung Highlight a Novel Role of B Cells in Sarcoidosis. Am J Respir Crit Care Med. 2021;204(12):1403–17.PubMedPubMedCentralCrossRef Bauer L, Müller LJ, Volkers SM, Heinrich F, Mashreghi MF, Ruppert C, Sander LE, Hutloff A. Follicular Helper-like T Cells in the Lung Highlight a Novel Role of B Cells in Sarcoidosis. Am J Respir Crit Care Med. 2021;204(12):1403–17.PubMedPubMedCentralCrossRef
108.
Zurück zum Zitat Ando M, Goto A, Takeno Y, Yamasue M, Komiya K, Umeki K, et al. Significant elevation of the levels of B-cell activating factor (BAFF) in patients with sarcoidosis. Clin Rheumatol. 2018;37(10):2833–8.PubMedCrossRef Ando M, Goto A, Takeno Y, Yamasue M, Komiya K, Umeki K, et al. Significant elevation of the levels of B-cell activating factor (BAFF) in patients with sarcoidosis. Clin Rheumatol. 2018;37(10):2833–8.PubMedCrossRef
109.
Zurück zum Zitat Lee NS, Barber L, Akula SM, Sigounas G, Kataria YP, Arce S. Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis. Clin Vaccine Immunol. 2011;18(8):1306–16.PubMedPubMedCentralCrossRef Lee NS, Barber L, Akula SM, Sigounas G, Kataria YP, Arce S. Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis. Clin Vaccine Immunol. 2011;18(8):1306–16.PubMedPubMedCentralCrossRef
110.
111.
Zurück zum Zitat Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell. 2010;40(2):310–22.PubMedPubMedCentralCrossRef Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell. 2010;40(2):310–22.PubMedPubMedCentralCrossRef
112.
Zurück zum Zitat Jung J, Zeng H, Horng T. Metabolism as a guiding force for immunity. Nat Cell Biol. 2019;21(1):85–93.PubMedCrossRef Jung J, Zeng H, Horng T. Metabolism as a guiding force for immunity. Nat Cell Biol. 2019;21(1):85–93.PubMedCrossRef
113.
114.
Zurück zum Zitat Pacheco Y, Lim CX, Weichhart T, Valeyre D, Bentaher A, Calender A. Sarcoidosis and the mTOR, Rac1, and autophagy triad. Trends Immunol. 2020;41(4):286–99.PubMedCrossRef Pacheco Y, Lim CX, Weichhart T, Valeyre D, Bentaher A, Calender A. Sarcoidosis and the mTOR, Rac1, and autophagy triad. Trends Immunol. 2020;41(4):286–99.PubMedCrossRef
115.
Zurück zum Zitat Linke M, Pham HT, Katholnig K, Schnoller T, Miller A, Demel F, et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017;18(3):293–302.PubMedPubMedCentralCrossRef Linke M, Pham HT, Katholnig K, Schnoller T, Miller A, Demel F, et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017;18(3):293–302.PubMedPubMedCentralCrossRef
116.
Zurück zum Zitat Pizzini A, Bacher H, Aichner M, Franchi A, Watzinger K, Tancevski I, et al. High expression of mTOR signaling in granulomatous lesions is not predictive for the clinical course of sarcoidosis. Respir Med. 2021;5(177): 106294.CrossRef Pizzini A, Bacher H, Aichner M, Franchi A, Watzinger K, Tancevski I, et al. High expression of mTOR signaling in granulomatous lesions is not predictive for the clinical course of sarcoidosis. Respir Med. 2021;5(177): 106294.CrossRef
117.
Zurück zum Zitat Kim YM, Park JM, Grunwald D, Kim DH. An expanded role for mTORC1 in autophagy. Mol Cell Oncol. 2016;3(1): e1010958.PubMedCrossRef Kim YM, Park JM, Grunwald D, Kim DH. An expanded role for mTORC1 in autophagy. Mol Cell Oncol. 2016;3(1): e1010958.PubMedCrossRef
118.
Zurück zum Zitat Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19(6):349–64.PubMedCrossRef Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19(6):349–64.PubMedCrossRef
119.
Zurück zum Zitat Crouser ED, Locke LW, Julian MW, Bicer S, Sadee W, White P, Schlesinger LS. Phagosome-regulated mTOR signalling during sarcoidosis granuloma biogenesis. Eur Respir J. 2021;57(3):2002695.PubMedCrossRef Crouser ED, Locke LW, Julian MW, Bicer S, Sadee W, White P, Schlesinger LS. Phagosome-regulated mTOR signalling during sarcoidosis granuloma biogenesis. Eur Respir J. 2021;57(3):2002695.PubMedCrossRef
120.
121.
Zurück zum Zitat Abedini A, Naderi Z, Kiani A, Marjani M, Mortaz E, Ghorbani F. The evaluation of interleukin-4 and interleukin-13 in the serum of pulmonary sarcoidosis and tuberculosis patients. J Res Med Sci. 2020;25:24.PubMedPubMedCentral Abedini A, Naderi Z, Kiani A, Marjani M, Mortaz E, Ghorbani F. The evaluation of interleukin-4 and interleukin-13 in the serum of pulmonary sarcoidosis and tuberculosis patients. J Res Med Sci. 2020;25:24.PubMedPubMedCentral
122.
Zurück zum Zitat Locke LW, Crouser ED, White P, Julian MW, Caceres EG, Papp AC, et al. IL-13-regulated macrophage polarization during granuloma formation in an in vitro human sarcoidosis model. Am J Respir Cell Mol Biol. 2019;60(1):84–95.PubMedPubMedCentralCrossRef Locke LW, Crouser ED, White P, Julian MW, Caceres EG, Papp AC, et al. IL-13-regulated macrophage polarization during granuloma formation in an in vitro human sarcoidosis model. Am J Respir Cell Mol Biol. 2019;60(1):84–95.PubMedPubMedCentralCrossRef
124.
Zurück zum Zitat Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–73.PubMed Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–73.PubMed
125.
Zurück zum Zitat Garcia-Colmenero L, Sanchez-Schmidt JM, Barranco C, Pujol RM. The natural history of cutaneous sarcoidosis. Clinical spectrum and histological analysis of 40 cases. Int J Dermatol. 2019;58(2):178–84.PubMedCrossRef Garcia-Colmenero L, Sanchez-Schmidt JM, Barranco C, Pujol RM. The natural history of cutaneous sarcoidosis. Clinical spectrum and histological analysis of 40 cases. Int J Dermatol. 2019;58(2):178–84.PubMedCrossRef
126.
Zurück zum Zitat Mana J, Marcoval J, Graells J, Salazar A, Peyri J, Pujol R. Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Arch Dermatol. 1997;133(7):882–8.PubMedCrossRef Mana J, Marcoval J, Graells J, Salazar A, Peyri J, Pujol R. Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Arch Dermatol. 1997;133(7):882–8.PubMedCrossRef
127.
Zurück zum Zitat Villa-Ruiz C, Lo K, Desai S, Vleugels RA, Imadojemu S. Practice gaps in the evaluation of systemic involvement in patients with cutaneous sarcoidosis presenting to a dermatologist: a retrospective review of 48 patients. J Am Acad Dermatol. 2021;85(3):794–6.PubMedCrossRef Villa-Ruiz C, Lo K, Desai S, Vleugels RA, Imadojemu S. Practice gaps in the evaluation of systemic involvement in patients with cutaneous sarcoidosis presenting to a dermatologist: a retrospective review of 48 patients. J Am Acad Dermatol. 2021;85(3):794–6.PubMedCrossRef
128.
Zurück zum Zitat Ribeiro Neto ML, Jellis CL, Joyce E, Callahan TD, Hachamovitch R, Culver DA. Update in cardiac sarcoidosis. Ann Am Thorac Soc. 2019;16(11):1341–50.PubMedCrossRef Ribeiro Neto ML, Jellis CL, Joyce E, Callahan TD, Hachamovitch R, Culver DA. Update in cardiac sarcoidosis. Ann Am Thorac Soc. 2019;16(11):1341–50.PubMedCrossRef
129.
Zurück zum Zitat Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther. 2016;6(1):50–63.PubMedPubMedCentral Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther. 2016;6(1):50–63.PubMedPubMedCentral
130.
Zurück zum Zitat Crouser ED, Maier LA, Wilson KC, Bonham CA, Morgenthau AS, Patterson KC, et al. Diagnosis and detection of sarcoidosis. An Official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(8):e26–51.PubMedPubMedCentralCrossRef Crouser ED, Maier LA, Wilson KC, Bonham CA, Morgenthau AS, Patterson KC, et al. Diagnosis and detection of sarcoidosis. An Official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(8):e26–51.PubMedPubMedCentralCrossRef
131.
Zurück zum Zitat Ungprasert P, Ryu JH, Matteson EL. Clinical manifestations, diagnosis, and treatment of sarcoidosis. Mayo Clin Proc Innov Qual Outcomes. 2019;3(3):358–75.PubMedPubMedCentralCrossRef Ungprasert P, Ryu JH, Matteson EL. Clinical manifestations, diagnosis, and treatment of sarcoidosis. Mayo Clin Proc Innov Qual Outcomes. 2019;3(3):358–75.PubMedPubMedCentralCrossRef
132.
Zurück zum Zitat Yeung H, Farber S, Birnbaum BK, Dunham J, Ogdie A, Patterson KC, et al. Reliability and validity of cutaneous sarcoidosis outcome instruments among dermatologists, pulmonologists, and rheumatologists. JAMA Dermatol. 2015;151(12):1317–22.PubMedCrossRef Yeung H, Farber S, Birnbaum BK, Dunham J, Ogdie A, Patterson KC, et al. Reliability and validity of cutaneous sarcoidosis outcome instruments among dermatologists, pulmonologists, and rheumatologists. JAMA Dermatol. 2015;151(12):1317–22.PubMedCrossRef
133.
Zurück zum Zitat Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol. 2012;148(2):262–4.PubMedCrossRef Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol. 2012;148(2):262–4.PubMedCrossRef
134.
Zurück zum Zitat Baughman RP, Judson MA, Teirstein A, Lower EE, Lo K, Schlenker-Herceg R, et al. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol. 2008;9(3):155–61.PubMedCrossRef Baughman RP, Judson MA, Teirstein A, Lower EE, Lo K, Schlenker-Herceg R, et al. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol. 2008;9(3):155–61.PubMedCrossRef
135.
Zurück zum Zitat Drake WP, Oswald-Richter K, Richmond BW, Isom J, Burke VE, Algood H, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol. 2013;149(9):1040–9.PubMedPubMedCentralCrossRef Drake WP, Oswald-Richter K, Richmond BW, Isom J, Burke VE, Algood H, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol. 2013;149(9):1040–9.PubMedPubMedCentralCrossRef
136.
Zurück zum Zitat Rosenbach M, Yeung H, Chu EY, Kim EJ, Payne AS, Takeshita J, et al. Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. JAMA Dermatol. 2013;149(5):550–6.PubMedCrossRef Rosenbach M, Yeung H, Chu EY, Kim EJ, Payne AS, Takeshita J, et al. Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. JAMA Dermatol. 2013;149(5):550–6.PubMedCrossRef
137.
Zurück zum Zitat Noe MH, Gelfand JM, Bryer JS, Price SN, Judson MA, Rosenbach M. Responsiveness to change and establishment of the minimal clinically important difference for the cutaneous sarcoidosis activity and morphology instrument. JAMA Dermatol. 2020;156(1):98–9.PubMedCrossRef Noe MH, Gelfand JM, Bryer JS, Price SN, Judson MA, Rosenbach M. Responsiveness to change and establishment of the minimal clinically important difference for the cutaneous sarcoidosis activity and morphology instrument. JAMA Dermatol. 2020;156(1):98–9.PubMedCrossRef
138.
Zurück zum Zitat Caplan A, Rosenbach M, Imadojemu S. Cutaneous sarcoidosis. Semin Respir Crit Care Med. 2020;41(5):689–99.PubMedCrossRef Caplan A, Rosenbach M, Imadojemu S. Cutaneous sarcoidosis. Semin Respir Crit Care Med. 2020;41(5):689–99.PubMedCrossRef
139.
Zurück zum Zitat Hasegawa T, Suga Y, Mizuno Y, Haruna K, Ikeda S. Photodynamic therapy using intense pulsed light for cutaneous sarcoidosis. J Dermatol. 2012;39(6):564–5.PubMedCrossRef Hasegawa T, Suga Y, Mizuno Y, Haruna K, Ikeda S. Photodynamic therapy using intense pulsed light for cutaneous sarcoidosis. J Dermatol. 2012;39(6):564–5.PubMedCrossRef
140.
Zurück zum Zitat Green CM. Topical tacrolimus for the treatment of cutaneous sarcoidosis. Clin Exp Dermatol. 2007;32(4):457–8.PubMedCrossRef Green CM. Topical tacrolimus for the treatment of cutaneous sarcoidosis. Clin Exp Dermatol. 2007;32(4):457–8.PubMedCrossRef
141.
Zurück zum Zitat Singh SK, Singh S, Pandey SS. Cutaneous sarcoidosis without systemic involvement: response to intralesional corticosteroid. Indian J Dermatol Venereol Leprol. 1996;62(4):273–4.PubMedCrossRef Singh SK, Singh S, Pandey SS. Cutaneous sarcoidosis without systemic involvement: response to intralesional corticosteroid. Indian J Dermatol Venereol Leprol. 1996;62(4):273–4.PubMedCrossRef
142.
Zurück zum Zitat Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol. 1990;23(3 Pt 1):487–9.PubMedCrossRef Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol. 1990;23(3 Pt 1):487–9.PubMedCrossRef
143.
Zurück zum Zitat Park MK, Fontana, Jr, Babaali H, Gilbert-McClain LI, Stylianou M, Joo J, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):121-31. Park MK, Fontana, Jr, Babaali H, Gilbert-McClain LI, Stylianou M, Joo J, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):121-31.
144.
Zurück zum Zitat Imadojemu SWK, Noe M, English JC, Rosenbach M. Cutaneous sarcoidosis. In: Baughman RPVD, editor. Sarcoidosis, a clinician’s guide. Amsterdam: Elsevier; 2019. p. 127–44. Imadojemu SWK, Noe M, English JC, Rosenbach M. Cutaneous sarcoidosis. In: Baughman RPVD, editor. Sarcoidosis, a clinician’s guide. Amsterdam: Elsevier; 2019. p. 127–44.
145.
Zurück zum Zitat Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs. 2008;68(10):1361–83.PubMedCrossRef Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs. 2008;68(10):1361–83.PubMedCrossRef
146.
Zurück zum Zitat Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, Rottoli P, Nunes H, Lower EE, Judson MA, Israel-Biet D, Grutters JC, Drent M, Culver DA, Bonella F, Antoniou K, Martone F, Quadder B, Spitzer G, Nagavci B, Tonia T, Rigau D, Ouellette DR. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079.PubMedCrossRef Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, Rottoli P, Nunes H, Lower EE, Judson MA, Israel-Biet D, Grutters JC, Drent M, Culver DA, Bonella F, Antoniou K, Martone F, Quadder B, Spitzer G, Nagavci B, Tonia T, Rigau D, Ouellette DR. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079.PubMedCrossRef
147.
Zurück zum Zitat Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: gastrointestinal and endocrinologic side effects. J Am Acad Dermatol. 2017;76(1):11–6.PubMedCrossRef Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: gastrointestinal and endocrinologic side effects. J Am Acad Dermatol. 2017;76(1):11–6.PubMedCrossRef
148.
Zurück zum Zitat Paolino A, Galloway J, Birring S, Brex P, Larkin G, Patel A, et al. Clinical phenotypes and therapeutic responses in cutaneous-predominant sarcoidosis: 6-year experience in a tertiary referral service. Clin Exp Dermatol. 2021;46(6):1038–45.PubMedCrossRef Paolino A, Galloway J, Birring S, Brex P, Larkin G, Patel A, et al. Clinical phenotypes and therapeutic responses in cutaneous-predominant sarcoidosis: 6-year experience in a tertiary referral service. Clin Exp Dermatol. 2021;46(6):1038–45.PubMedCrossRef
149.
Zurück zum Zitat Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–73.PubMedCrossRef Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–73.PubMedCrossRef
150.
Zurück zum Zitat Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol. 2005;141(7):910–1.PubMedCrossRef Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol. 2005;141(7):910–1.PubMedCrossRef
151.
Zurück zum Zitat Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest. 2009;135(2):468–76.PubMedCrossRef Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest. 2009;135(2):468–76.PubMedCrossRef
152.
Zurück zum Zitat Field S, Regan AO, Sheahan K, Collins P. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol. 2010;35(7):795–6.PubMedCrossRef Field S, Regan AO, Sheahan K, Collins P. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol. 2010;35(7):795–6.PubMedCrossRef
153.
Zurück zum Zitat Thielen AM, Barde C, Saurat JH, Laffitte E. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Dermatology. 2009;219(1):59–62.PubMedCrossRef Thielen AM, Barde C, Saurat JH, Laffitte E. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Dermatology. 2009;219(1):59–62.PubMedCrossRef
154.
Zurück zum Zitat Heidelberger V, Ingen-Housz-Oro S, Marquet A, Mahevas M, Bessis D, Bouillet L, et al. Efficacy and tolerance of anti-tumor necrosis factor alpha agents in cutaneous sarcoidosis: a French study of 46 cases. JAMA Dermatol. 2017;153(7):681–5.PubMedPubMedCentralCrossRef Heidelberger V, Ingen-Housz-Oro S, Marquet A, Mahevas M, Bessis D, Bouillet L, et al. Efficacy and tolerance of anti-tumor necrosis factor alpha agents in cutaneous sarcoidosis: a French study of 46 cases. JAMA Dermatol. 2017;153(7):681–5.PubMedPubMedCentralCrossRef
155.
Zurück zum Zitat Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48(8):883–6.CrossRef Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48(8):883–6.CrossRef
156.
Zurück zum Zitat Fok KC, Ng WW, Henderson CJ, Connor SJ. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J Crohns Colitis. 2012;6(6):708–12.PubMedCrossRef Fok KC, Ng WW, Henderson CJ, Connor SJ. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J Crohns Colitis. 2012;6(6):708–12.PubMedCrossRef
157.
Zurück zum Zitat Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Seve P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18(11): 102390.PubMedCrossRef Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Seve P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18(11): 102390.PubMedCrossRef
158.
Zurück zum Zitat Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 1):i43–54.CrossRef Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 1):i43–54.CrossRef
159.
Zurück zum Zitat Wei JJ, Kallenbach LR, Kreider M, Leung TH, Rosenbach M. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Rep. 2019;5(4):360–1.PubMedPubMedCentralCrossRef Wei JJ, Kallenbach LR, Kreider M, Leung TH, Rosenbach M. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Rep. 2019;5(4):360–1.PubMedPubMedCentralCrossRef
160.
Zurück zum Zitat Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540–6.PubMedPubMedCentralCrossRef Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540–6.PubMedPubMedCentralCrossRef
161.
Zurück zum Zitat Rotenberg C, Besnard V, Brillet PY, Giraudier S, Nunes H, Valeyre D. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir J. 2018 Dec 20;52(6):1801482. Rotenberg C, Besnard V, Brillet PY, Giraudier S, Nunes H, Valeyre D. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir J. 2018 Dec 20;52(6):1801482.
162.
Zurück zum Zitat Rosenbach M. Janus kinase inhibitors offer promise for a new era of targeted treatment for granulomatous disorders. J Am Acad Dermatol. 2020;82(3):e91–2.PubMedCrossRef Rosenbach M. Janus kinase inhibitors offer promise for a new era of targeted treatment for granulomatous disorders. J Am Acad Dermatol. 2020;82(3):e91–2.PubMedCrossRef
163.
Zurück zum Zitat Scheinberg M, Maluf F, Wagner J. Steroid-resistant sarcoidosis treated with baricitinib. Ann Rheum Dis. 2020;79(9):1259–60.PubMedCrossRef Scheinberg M, Maluf F, Wagner J. Steroid-resistant sarcoidosis treated with baricitinib. Ann Rheum Dis. 2020;79(9):1259–60.PubMedCrossRef
164.
Zurück zum Zitat Levraut M, Martis N, Viau P, Suarez F, Queyrel V. Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib. Ann Rheum Dis. 2019;78(11):1606–7.PubMedCrossRef Levraut M, Martis N, Viau P, Suarez F, Queyrel V. Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib. Ann Rheum Dis. 2019;78(11):1606–7.PubMedCrossRef
165.
Zurück zum Zitat Judson MA. Corticosteroid-sparing drugs in sarcoidosis: how should we assess them? Lung. 2021;199(2):85–6.PubMedCrossRef Judson MA. Corticosteroid-sparing drugs in sarcoidosis: how should we assess them? Lung. 2021;199(2):85–6.PubMedCrossRef
166.
Zurück zum Zitat Friedman MA, Le B, Stevens J, Desmarais J, Seifer D, Ogle K, et al. Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study. Lung. 2021;199(2):147–53.PubMedPubMedCentralCrossRef Friedman MA, Le B, Stevens J, Desmarais J, Seifer D, Ogle K, et al. Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study. Lung. 2021;199(2):147–53.PubMedPubMedCentralCrossRef
167.
Zurück zum Zitat Alam M, Fang V, Rosenbach M. Treatment of cutaneous sarcoidosis with tofacitinib 2% ointment and extra virgin olive oil. JAAD Case Rep. 2021;9:1–3.PubMedCrossRef Alam M, Fang V, Rosenbach M. Treatment of cutaneous sarcoidosis with tofacitinib 2% ointment and extra virgin olive oil. JAAD Case Rep. 2021;9:1–3.PubMedCrossRef
168.
Zurück zum Zitat Singh K, Wang A, Heald P, McNiff JM, Suozzi K, King B, et al. Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy. JAAD Case Rep. 2021;7:122–4.PubMedCrossRef Singh K, Wang A, Heald P, McNiff JM, Suozzi K, King B, et al. Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy. JAAD Case Rep. 2021;7:122–4.PubMedCrossRef
169.
Zurück zum Zitat Wu KK, Dao H Jr. Off-label dermatologic uses of IL-17 inhibitors. J Dermatol Treat. 2020;9:1–7. Wu KK, Dao H Jr. Off-label dermatologic uses of IL-17 inhibitors. J Dermatol Treat. 2020;9:1–7.
170.
Zurück zum Zitat Sambharia MMT, Ramakrishna S. Worsening of pulmonary sarcoidosis induced by ixekizumab: a rare paradox. Chest. 2018;154:898A.CrossRef Sambharia MMT, Ramakrishna S. Worsening of pulmonary sarcoidosis induced by ixekizumab: a rare paradox. Chest. 2018;154:898A.CrossRef
171.
Zurück zum Zitat Eichhoff G. Management with secukinumab of tumour necrosis factor inhibitor-induced pulmonary sarcoidosis-like reaction in a patient with psoriasis. Clin Exp Dermatol. 2020;45(4):455–6.PubMedCrossRef Eichhoff G. Management with secukinumab of tumour necrosis factor inhibitor-induced pulmonary sarcoidosis-like reaction in a patient with psoriasis. Clin Exp Dermatol. 2020;45(4):455–6.PubMedCrossRef
172.
Zurück zum Zitat Toussirot E, Bernard C, Bossert M. Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis. Clin Exp Rheumatol. 2019;37(2):344–5.PubMed Toussirot E, Bernard C, Bossert M. Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis. Clin Exp Rheumatol. 2019;37(2):344–5.PubMed
173.
Zurück zum Zitat Nyckowski TCR, Wilson J. Sarcoidosis developing during secukinumab therapy: case report. SKIN J Cutan Med. 2017;1:95–9.CrossRef Nyckowski TCR, Wilson J. Sarcoidosis developing during secukinumab therapy: case report. SKIN J Cutan Med. 2017;1:95–9.CrossRef
174.
175.
Zurück zum Zitat Powell MD, Read KA, Sreekumar BK, Jones DM, Oestreich KJ. IL-12 signaling drives the differentiation and function of a TH1-derived TFH1-like cell population. Sci Rep. 2019;9(1):13991.PubMedPubMedCentralCrossRef Powell MD, Read KA, Sreekumar BK, Jones DM, Oestreich KJ. IL-12 signaling drives the differentiation and function of a TH1-derived TFH1-like cell population. Sci Rep. 2019;9(1):13991.PubMedPubMedCentralCrossRef
176.
Zurück zum Zitat Mroz RM, Korniluk M, Stasiak-Barmuta A, Chyczewska E. Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. J Physiol Pharmacol. 2008;59(Suppl 6):507–13.PubMed Mroz RM, Korniluk M, Stasiak-Barmuta A, Chyczewska E. Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. J Physiol Pharmacol. 2008;59(Suppl 6):507–13.PubMed
177.
Zurück zum Zitat Shigehara K, Shijubo N, Ohmichi M, Kamiguchi K, Takahashi R, Morita-Ichimura S, et al. Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis. Clin Exp Immunol. 2003;132(1):152–7.PubMedPubMedCentralCrossRef Shigehara K, Shijubo N, Ohmichi M, Kamiguchi K, Takahashi R, Morita-Ichimura S, et al. Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis. Clin Exp Immunol. 2003;132(1):152–7.PubMedPubMedCentralCrossRef
178.
Zurück zum Zitat Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535–45.PubMedPubMedCentralCrossRef Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535–45.PubMedPubMedCentralCrossRef
179.
Zurück zum Zitat Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296–307.PubMedCrossRef Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296–307.PubMedCrossRef
180.
Zurück zum Zitat Thomas AS, Rosenbaum JT. Poor control of sarcoidosis-related panuveitis with an antibody to IL-23. Ocul Immunol Inflamm. 2020;28(3):491–3.PubMedCrossRef Thomas AS, Rosenbaum JT. Poor control of sarcoidosis-related panuveitis with an antibody to IL-23. Ocul Immunol Inflamm. 2020;28(3):491–3.PubMedCrossRef
181.
Zurück zum Zitat Gad MM, Bazarbashi N, Kaur M, Gupta A. Sarcoid-like phenomenon—ustekinumab induced granulomatous reaction mimicking diffuse metastatic disease: a case report and review of the literature. J Med Case Rep. 2019;13(1):257.PubMedPubMedCentralCrossRef Gad MM, Bazarbashi N, Kaur M, Gupta A. Sarcoid-like phenomenon—ustekinumab induced granulomatous reaction mimicking diffuse metastatic disease: a case report and review of the literature. J Med Case Rep. 2019;13(1):257.PubMedPubMedCentralCrossRef
182.
Zurück zum Zitat Powell JB, Matthews P, Rattehalli R, Woodhead F, Perkins P, Powell G, et al. Acute systemic sarcoidosis complicating ustekinumab therapy for chronic plaque psoriasis. Br J Dermatol. 2015;172(3):834–6.PubMedCrossRef Powell JB, Matthews P, Rattehalli R, Woodhead F, Perkins P, Powell G, et al. Acute systemic sarcoidosis complicating ustekinumab therapy for chronic plaque psoriasis. Br J Dermatol. 2015;172(3):834–6.PubMedCrossRef
183.
Zurück zum Zitat Kobak S, Semiz H. Ustekinumab-induced sarcoidosis in a patient with psoriatic arthritis. Curr Drug Saf. 2020;15(2):163–6.PubMedCrossRef Kobak S, Semiz H. Ustekinumab-induced sarcoidosis in a patient with psoriatic arthritis. Curr Drug Saf. 2020;15(2):163–6.PubMedCrossRef
184.
Zurück zum Zitat Hunninghake GW, Crystal RG. Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. J Clin Invest. 1981;67(1):86–92.PubMedPubMedCentralCrossRef Hunninghake GW, Crystal RG. Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. J Clin Invest. 1981;67(1):86–92.PubMedPubMedCentralCrossRef
185.
Zurück zum Zitat Cinetto F, Compagno N, Scarpa R, Malipiero G, Agostini C. Rituximab in refractory sarcoidosis: a single centre experience. Clin Mol Allergy. 2015;13(1):19.PubMedPubMedCentralCrossRef Cinetto F, Compagno N, Scarpa R, Malipiero G, Agostini C. Rituximab in refractory sarcoidosis: a single centre experience. Clin Mol Allergy. 2015;13(1):19.PubMedPubMedCentralCrossRef
186.
Zurück zum Zitat Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Thone J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018;11:1756286418805732.PubMedPubMedCentralCrossRef Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Thone J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018;11:1756286418805732.PubMedPubMedCentralCrossRef
187.
Zurück zum Zitat Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010;75(6):568–70.PubMedCrossRef Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010;75(6):568–70.PubMedCrossRef
188.
Zurück zum Zitat Krause ML, Cooper LT, Chareonthaitawee P, Amin S. Successful use of rituximab in refractory cardiac sarcoidosis. Rheumatology (Oxford). 2016;55(1):189–91.CrossRef Krause ML, Cooper LT, Chareonthaitawee P, Amin S. Successful use of rituximab in refractory cardiac sarcoidosis. Rheumatology (Oxford). 2016;55(1):189–91.CrossRef
189.
Zurück zum Zitat Elwazir M, Krause ML, Bois JP, Christopoulos G, Kendi AT, Cooper JLT, Jouni H, Abouezzeddine OF, Chareonthaitawee P, Abdelshafee M, Amin S. Rituximab for the Treatment of Refractory Cardiac Sarcoidosis: A Single-Center Experience. J Card Fail. 2022;28(2):247–58.PubMedCrossRef Elwazir M, Krause ML, Bois JP, Christopoulos G, Kendi AT, Cooper JLT, Jouni H, Abouezzeddine OF, Chareonthaitawee P, Abdelshafee M, Amin S. Rituximab for the Treatment of Refractory Cardiac Sarcoidosis: A Single-Center Experience. J Card Fail. 2022;28(2):247–58.PubMedCrossRef
190.
Zurück zum Zitat Sweiss NJ, Lower EE, Mirsaeidi M, Dudek S, Garcia JG, Perkins D, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43(5):1525–8.PubMedPubMedCentralCrossRef Sweiss NJ, Lower EE, Mirsaeidi M, Dudek S, Garcia JG, Perkins D, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43(5):1525–8.PubMedPubMedCentralCrossRef
191.
Zurück zum Zitat Vesely NC, Thomas RM, Rudnick E, Longo MI. Scar sarcoidosis following rituximab therapy. Dermatol Ther. 2020;33(6): e13693.PubMedCrossRef Vesely NC, Thomas RM, Rudnick E, Longo MI. Scar sarcoidosis following rituximab therapy. Dermatol Ther. 2020;33(6): e13693.PubMedCrossRef
192.
Zurück zum Zitat Pescitelli L, Emmi G, Tripo L, Lazzeri L, Urban ML, Silvesri E, et al. Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect? Eur J Dermatol. 2017;27(6):667–8.PubMedCrossRef Pescitelli L, Emmi G, Tripo L, Lazzeri L, Urban ML, Silvesri E, et al. Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect? Eur J Dermatol. 2017;27(6):667–8.PubMedCrossRef
193.
Zurück zum Zitat Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001;137(1):69–73.PubMedCrossRef Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001;137(1):69–73.PubMedCrossRef
194.
Zurück zum Zitat Marshall TG, Marshall FE. Sarcoidosis succumbs to antibiotics—implications for autoimmune disease. Autoimmun Rev. 2004;3(4):295–300.PubMedCrossRef Marshall TG, Marshall FE. Sarcoidosis succumbs to antibiotics—implications for autoimmune disease. Autoimmun Rev. 2004;3(4):295–300.PubMedCrossRef
195.
Zurück zum Zitat Beijer E, Seldenrijk K, Eishi Y, Uchida K, Damen J, Grutters JC, Veltkamp M. Presence of Propionibacterium acnes in granulomas associates with a chronic disease course in Dutch sarcoidosis patients. ERJ Open Res. 2021;7(1):00486-2020.PubMedPubMedCentralCrossRef Beijer E, Seldenrijk K, Eishi Y, Uchida K, Damen J, Grutters JC, Veltkamp M. Presence of Propionibacterium acnes in granulomas associates with a chronic disease course in Dutch sarcoidosis patients. ERJ Open Res. 2021;7(1):00486-2020.PubMedPubMedCentralCrossRef
196.
Zurück zum Zitat Ishibashi K, Eishi Y, Tahara N, Asakura M, Sakamoto N, Nakamura K, et al. Japanese Antibacterial Drug Management for Cardiac Sarcoidosis (J-ACNES): a multicenter, open-label, randomized, controlled study. J Arrhythm. 2018;34(5):520–6.PubMedPubMedCentralCrossRef Ishibashi K, Eishi Y, Tahara N, Asakura M, Sakamoto N, Nakamura K, et al. Japanese Antibacterial Drug Management for Cardiac Sarcoidosis (J-ACNES): a multicenter, open-label, randomized, controlled study. J Arrhythm. 2018;34(5):520–6.PubMedPubMedCentralCrossRef
197.
Zurück zum Zitat Drake WP, Richmond BW, Oswald-Richter K, Yu C, Isom JM, Worrell JA, et al. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(3):201–11.PubMed Drake WP, Richmond BW, Oswald-Richter K, Yu C, Isom JM, Worrell JA, et al. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(3):201–11.PubMed
198.
Zurück zum Zitat Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–57.PubMedCrossRef Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–57.PubMedCrossRef
199.
Zurück zum Zitat Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335–45.PubMedPubMedCentralCrossRef Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335–45.PubMedPubMedCentralCrossRef
200.
Zurück zum Zitat Soric Hosman I, Kos I, Lamot L. Serum amyloid A in inflammatory rheumatic diseases: a compendious review of a renowned biomarker. Front Immunol. 2020;11: 631299.PubMedCrossRef Soric Hosman I, Kos I, Lamot L. Serum amyloid A in inflammatory rheumatic diseases: a compendious review of a renowned biomarker. Front Immunol. 2020;11: 631299.PubMedCrossRef
202.
Zurück zum Zitat Chen ES, Song Z, Willett MH, Heine S, Yung RC, Liu MC, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181(4):360–73.PubMedCrossRef Chen ES, Song Z, Willett MH, Heine S, Yung RC, Liu MC, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181(4):360–73.PubMedCrossRef
203.
Zurück zum Zitat Schanz S, Schmalzing M, Guenova E, Metzler G, Ulmer A, Kotter I, et al. Interstitial granulomatous dermatitis with arthritis responding to tocilizumab. Arch Dermatol. 2012;148(1):17–20.PubMedCrossRef Schanz S, Schmalzing M, Guenova E, Metzler G, Ulmer A, Kotter I, et al. Interstitial granulomatous dermatitis with arthritis responding to tocilizumab. Arch Dermatol. 2012;148(1):17–20.PubMedCrossRef
204.
Zurück zum Zitat Sharp M, Donnelly SC, Moller DR. Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. Respir Med X. 2019;1:100004.PubMedPubMedCentral Sharp M, Donnelly SC, Moller DR. Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. Respir Med X. 2019;1:100004.PubMedPubMedCentral
205.
Zurück zum Zitat Theodosiou G, Luu H, Svensson A. Tocilizumab-induced sarcoidosis-like reaction in a patient with giant cell arteritis. Clinical implications of a paradoxical phenomenon. Int J Dermatol. 2020;59(7):888–9.PubMedCrossRef Theodosiou G, Luu H, Svensson A. Tocilizumab-induced sarcoidosis-like reaction in a patient with giant cell arteritis. Clinical implications of a paradoxical phenomenon. Int J Dermatol. 2020;59(7):888–9.PubMedCrossRef
206.
Zurück zum Zitat Lambert N, Hansen I, El Moussaoui M, Giot JB, Vercheval C, Lommers É, Somja J, Moutschen M, Maquet P. Lung and liver sarcoidosis-like reaction induced by tocilizumab. Br J Clin Pharmacol. 2021;87(12):4848–52.PubMedCrossRef Lambert N, Hansen I, El Moussaoui M, Giot JB, Vercheval C, Lommers É, Somja J, Moutschen M, Maquet P. Lung and liver sarcoidosis-like reaction induced by tocilizumab. Br J Clin Pharmacol. 2021;87(12):4848–52.PubMedCrossRef
207.
Zurück zum Zitat Nutz A, Pernet C, Combe B, Cohen JD. Sarcoidosis induced by tocilizumab: a paradoxical event? J Rheumatol. 2013;40(10):1773–4.PubMedCrossRef Nutz A, Pernet C, Combe B, Cohen JD. Sarcoidosis induced by tocilizumab: a paradoxical event? J Rheumatol. 2013;40(10):1773–4.PubMedCrossRef
208.
Zurück zum Zitat Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–55.PubMedCrossRef Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–55.PubMedCrossRef
209.
Zurück zum Zitat Obi ON, Lower EE, Baughman RP. Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. Expert Rev Clin Pharmacol. 2021;14(2):179–210.PubMedCrossRef Obi ON, Lower EE, Baughman RP. Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. Expert Rev Clin Pharmacol. 2021;14(2):179–210.PubMedCrossRef
210.
Zurück zum Zitat Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159(2):508–11.PubMedCrossRef Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159(2):508–11.PubMedCrossRef
211.
Zurück zum Zitat Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest. 2003;124(4):1526–32.PubMedCrossRef Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest. 2003;124(4):1526–32.PubMedCrossRef
212.
Zurück zum Zitat Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997;155(5):1665–9.PubMedCrossRef Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997;155(5):1665–9.PubMedCrossRef
213.
Zurück zum Zitat Imadojemu S, Wanat KA, Noe M, English JC, Rosenbach M. Cutaneous sarcoidosis. In: RP B, editor. Sarcoidosis, a clinician’s guide. Amsterdam: Elsevier; 2019. p. 127–44. Imadojemu S, Wanat KA, Noe M, English JC, Rosenbach M. Cutaneous sarcoidosis. In: RP B, editor. Sarcoidosis, a clinician’s guide. Amsterdam: Elsevier; 2019. p. 127–44.
214.
Zurück zum Zitat Baughman RP, Judson MA, Culver DA, Birring SS, Parambil J, Zeigler J, et al. Roflumilast (Daliresp(R)) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis. 2021;38(3): e2021035.PubMedPubMedCentral Baughman RP, Judson MA, Culver DA, Birring SS, Parambil J, Zeigler J, et al. Roflumilast (Daliresp(R)) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis. 2021;38(3): e2021035.PubMedPubMedCentral
215.
Zurück zum Zitat Manzia TM, Bellini MI, Corona L, Toti L, Fratoni S, Cillis A, et al. Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of rapamune after liver transplantation. Transpl Int. 2011;24(8):e69-70.PubMedCrossRef Manzia TM, Bellini MI, Corona L, Toti L, Fratoni S, Cillis A, et al. Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of rapamune after liver transplantation. Transpl Int. 2011;24(8):e69-70.PubMedCrossRef
216.
Zurück zum Zitat Gupta N, Bleesing JH, McCormack FX. Successful response to treatment with sirolimus in pulmonary sarcoidosis. Am J Respir Crit Care Med. 2020;202(9):e119–20.PubMedCrossRef Gupta N, Bleesing JH, McCormack FX. Successful response to treatment with sirolimus in pulmonary sarcoidosis. Am J Respir Crit Care Med. 2020;202(9):e119–20.PubMedCrossRef
217.
Zurück zum Zitat Kelleher KJ, Russell J, Killeen OG, Leahy TR. Treatment-recalcitrant laryngeal sarcoidosis responsive to sirolimus. BMJ Case Rep. 2020;13(8):e235372.PubMedCrossRef Kelleher KJ, Russell J, Killeen OG, Leahy TR. Treatment-recalcitrant laryngeal sarcoidosis responsive to sirolimus. BMJ Case Rep. 2020;13(8):e235372.PubMedCrossRef
218.
Zurück zum Zitat Yanardag H, Tetikkurt C, Bilir M, Yilmaz E. Association of HLA antigens with the clinical course of sarcoidosis and familial disease. Monaldi Arch Chest Dis. 2017;87(3):835.PubMedCrossRef Yanardag H, Tetikkurt C, Bilir M, Yilmaz E. Association of HLA antigens with the clinical course of sarcoidosis and familial disease. Monaldi Arch Chest Dis. 2017;87(3):835.PubMedCrossRef
219.
Zurück zum Zitat Grunewald J, Eklund A. Lofgren’s syndrome: human leukocyte antigen strongly influences the disease course. Am J Respir Crit Care Med. 2009;179(4):307–12.PubMedCrossRef Grunewald J, Eklund A. Lofgren’s syndrome: human leukocyte antigen strongly influences the disease course. Am J Respir Crit Care Med. 2009;179(4):307–12.PubMedCrossRef
220.
Zurück zum Zitat Morais A, Lima B, Alves H, Melo N, Mota PC, Marques A, et al. Associations between sarcoidosis clinical course and ANXA11 rs1049550 C/T, BTNL2 rs2076530 G/A, and HLA class I and II alleles. Clin Respir J. 2018;12(2):532–7.PubMedCrossRef Morais A, Lima B, Alves H, Melo N, Mota PC, Marques A, et al. Associations between sarcoidosis clinical course and ANXA11 rs1049550 C/T, BTNL2 rs2076530 G/A, and HLA class I and II alleles. Clin Respir J. 2018;12(2):532–7.PubMedCrossRef
221.
Zurück zum Zitat Rossman MD, Thompson B, Frederick M, Maliarik M, Iannuzzi MC, Rybicki BA, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. 2003;73(4):720–35.PubMedPubMedCentralCrossRef Rossman MD, Thompson B, Frederick M, Maliarik M, Iannuzzi MC, Rybicki BA, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. 2003;73(4):720–35.PubMedPubMedCentralCrossRef
222.
Zurück zum Zitat Garman L, Pezant N, Pastori A, Savoy KA, Li C, Levin AM, et al. Genome-wide association study of ocular sarcoidosis confirms HLA associations and implicates barrier function and autoimmunity in African Americans. Ocul Immunol Inflamm. 2021;29(2):244–9.PubMedCrossRef Garman L, Pezant N, Pastori A, Savoy KA, Li C, Levin AM, et al. Genome-wide association study of ocular sarcoidosis confirms HLA associations and implicates barrier function and autoimmunity in African Americans. Ocul Immunol Inflamm. 2021;29(2):244–9.PubMedCrossRef
223.
Zurück zum Zitat Naruse TK, Matsuzawa Y, Ota M, Katsuyama Y, Matsumori A, Hara M, et al. HLA-DQB1*0601 is primarily associated with the susceptibility to cardiac sarcoidosis. Tissue Antigens. 2000;56(1):52–7.PubMedCrossRef Naruse TK, Matsuzawa Y, Ota M, Katsuyama Y, Matsumori A, Hara M, et al. HLA-DQB1*0601 is primarily associated with the susceptibility to cardiac sarcoidosis. Tissue Antigens. 2000;56(1):52–7.PubMedCrossRef
Metadaten
Titel
The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy
verfasst von
Julie H. Wu
Sotonye Imadojemu
Avrom S. Caplan
Publikationsdatum
18.05.2022
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 4/2022
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-022-00693-0

Weitere Artikel der Ausgabe 4/2022

American Journal of Clinical Dermatology 4/2022 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.